<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04941599</url>
  </required_header>
  <id_info>
    <org_study_id>201575</org_study_id>
    <secondary_id>2P01HL116263-06</secondary_id>
    <nct_id>NCT04941599</nct_id>
  </id_info>
  <brief_title>2-Hydroxybenzylamine (2-HOBA) to Reduce HDL Modification and Improve HDL Function in Familial Hypercholesterolemia (FH)</brief_title>
  <official_title>2-Hydroxybenzylamine (2-HOBA) to Reduce HDL Modification and Improve HDL Function in Familial Hypercholesterolemia (FH)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vanderbilt University Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Heart, Lung, and Blood Institute (NHLBI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Vanderbilt University Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The Investigators will test the hypothesis that 2-HOBA will reduce modification of HDL and&#xD;
      LDL and improve HDL function in humans with heterozygous FH. The Investigators plan to first&#xD;
      study subjects with Familial Hypercholesterolemia (FH), treating them with 750 mg of 2-HOBA&#xD;
      or placebo every 8 hours for 6 weeks.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">August 15, 2021</start_date>
  <completion_date type="Anticipated">September 30, 2023</completion_date>
  <primary_completion_date type="Anticipated">September 30, 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>2-HOBA increases HDL cholesterol efflux capacity.</measure>
    <time_frame>Baseline to week 6</time_frame>
    <description>Change in HDL cholesterol efflux capacity will be measured by macrophage cholesterol efflux assay.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>2-HOBA reduces modification of HDL by Isolevuglandin (Iso-LG).</measure>
    <time_frame>Baseline to week 6</time_frame>
    <description>Measurement of the Iso-LG-lysine lactam by mass spectrometry.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>2-HOBA reduces modification of HDL by malondialdehyde (MDA).</measure>
    <time_frame>Baseline to week 6</time_frame>
    <description>Measurement of dilysyl-MDA cross-links by mass spectrometry.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Change in HDL anti-inflammatory function in an in vitro assay of macrophage cytokine production (IL-1B, TNFa, IL-6).</measure>
    <time_frame>Baseline to week 6</time_frame>
    <description>Measurement of changes in LPS-stimulated macrophage cytokine production(IL-1B, TNFa, IL-6).</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in HDL anti-oxidant function in an in vitro assay of macrophage reactive oxygen species production.</measure>
    <time_frame>Baseline to week 6</time_frame>
    <description>Measurement of changes in H2O2-stimulated macrophage reactive oxygen species</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in HDL microRNA and small noncoding ribonucleic acid (sRNA) composition</measure>
    <time_frame>Baseline to week 6</time_frame>
    <description>HDL microRNA and sRNA will be measured through high-throughput sequencing with quantitative polymerase chain reaction (qPCR) validation.</description>
  </other_outcome>
  <other_outcome>
    <measure>Effects of 2-HOBA on HDL and LDL subpopulation sizes</measure>
    <time_frame>Baseline to week 6</time_frame>
    <description>HDL and LDL subpopulation sizes and particle numbers will be measured by NMR</description>
  </other_outcome>
  <other_outcome>
    <measure>Effect of 2-HOBA on Endothelial Function as measured by Forearm Flow Mediated Dilatation.</measure>
    <time_frame>Baseline to week 6</time_frame>
    <description>Noninvasive measure of endothelial function uses an ultrasound-based method to measure arterial diameter in response to an increase in shear stress.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">72</enrollment>
  <condition>Familial Hypercholesterolemia</condition>
  <arm_group>
    <arm_group_label>2-Hydroxybenzylamine (2-HOBA)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>2-Hydroxybenzylamine (2-HOBA) 250 mg three tabs TID (po) for 6 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo- three tabs TID (po) for 6 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>2-Hydroxybenzylamine</intervention_name>
    <description>2-Hydroxybenzylamine (2-HOBA) 250 mg three tabs TID (po) for 6 weeks.</description>
    <arm_group_label>2-Hydroxybenzylamine (2-HOBA)</arm_group_label>
    <other_name>2-HOBA</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo 250 mg three tabs TID (po) for 6 weeks.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Individuals with heterozygous Familial Hypercholesterolemia.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Myocardial infarction or stroke within the last 6 months&#xD;
&#xD;
          -  unstable angina, symptoms of angina within the last 3 months&#xD;
&#xD;
          -  NYHA class III or IV heart failure or LVEF &lt; 30%&#xD;
&#xD;
          -  poorly controlled hypertension: SBP &gt; 180 mm Hg or DBP &gt; 110 mm Hg,&#xD;
&#xD;
          -  pregnancy,&#xD;
&#xD;
          -  evidence of a previous acute coronary syndrome,&#xD;
&#xD;
          -  current smokers,&#xD;
&#xD;
          -  individuals with Type 2 Diabetes Mellitus, obesity (BMI &gt; 30),&#xD;
&#xD;
          -  hypertriglyceridemia (fasting TG &gt; 250 mg/dl),&#xD;
&#xD;
          -  renal insufficiency (Cr &gt; 1.8),&#xD;
&#xD;
          -  hepatic disease (aspartate aminotransferase(AST) or alanine aminotransferase (ALT) &gt;&#xD;
             2x ULN),&#xD;
&#xD;
          -  hypothyroidism,&#xD;
&#xD;
          -  nephrotic syndrome,&#xD;
&#xD;
          -  rheumatoid arthritis,&#xD;
&#xD;
          -  systemic lupus erythematosus,&#xD;
&#xD;
          -  AIDS or HIV&#xD;
&#xD;
          -  history of malignancy of any organ in last 5 years.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>69 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>MacRae F. Linton, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Vanderbilt University Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Beth Meador, RN</last_name>
    <phone>6159361450</phone>
    <email>beth.meador@vumc.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Anca Ifrim, RN</last_name>
    <phone>6159361450</phone>
    <email>anca.ifrim@vumc.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Vanderbilt University Medical Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37212</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>June 18, 2021</study_first_submitted>
  <study_first_submitted_qc>June 18, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 28, 2021</study_first_posted>
  <last_update_submitted>July 6, 2021</last_update_submitted>
  <last_update_submitted_qc>July 6, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 12, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Vanderbilt University Medical Center</investigator_affiliation>
    <investigator_full_name>MacRae F. Linton, MD</investigator_full_name>
    <investigator_title>Professor of Medicine and Pharmacology</investigator_title>
  </responsible_party>
  <keyword>Familial Hypercholesterolemia</keyword>
  <keyword>HDL</keyword>
  <keyword>LDL</keyword>
  <keyword>2-HOBA</keyword>
  <keyword>HDL Function</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyperlipoproteinemia Type II</mesh_term>
    <mesh_term>Hypercholesterolemia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Individual participant data that underlie the results reported will be made available (including data dictionaries) after de-identification.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Analytic Code</ipd_info_type>
    <ipd_time_frame>The data will become available 3 months following publication of outcomes and will remain available for at least 5 years.</ipd_time_frame>
    <ipd_access_criteria>Data will be made available to researchers who provide a methodologically sound proposal that has been approved by the Vanderbilt Institutional Review Board and the study executive committee.</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

